Type-2 diabetes drug significantly reduces hospitalisations and deaths from heart failure

11 Nov 2015


Findings from a large clinical trial known as EMPA-REG OUTCOME were reported at the American Heart Association annual conference; they demonstrate for the first time that a type-2 diabetes drug, Jardiance, reduces risk of heart failure.

EurekAlert


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story